您的当前位置:首页 > 行业数据 > AK104治疗一线宫颈癌对比联合疗法适用患者增加PD-L1CPS<1部分,III期研究已达PFS终点
图片属性
图片格式:PNG 图片大小:275KB 图片尺寸:2304*1286
同报告图片
 / 4
AK104治疗一线宫颈癌对比联合疗法适用患者增加PD-L1CPS<1部分,III期研究已达PFS终点_第1页
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
AK104治疗一线宫颈癌对比联合疗法适用患者增加PD-L1CPS<1部分,III期研究已达PFS终点_第2页
fCDlk4HniYwgICAgICAgfCDljaDmr5QgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS18CnwgQkFJIFpFIEFOICB8IDM1JSAgfAp8IFRZVllUICAgICAgfCAyNSUgIHwKfCBBTCBSVUkgS0EgIHwgMTUlICB8CnwgS0VZVFJVREEgICB8IDEwJSAgfAp8IFRVTyBZSSAgICAgfCA1JSAgIHwKfCBIQU4gU0hJIFpIVUFORyB8IDMlICB8CnwgVEVDRU5UUklRICB8IDIlICAgfAp8IE9QRElWTyAgICAgfCAyJSAgIHwKfCBBTiBOSSBLRSAgIHwgMSUgICB8CnwgRU4gV0VJIERBICB8IDElICAgfAp8IE9USEVSUyAgICAgfCAxJSAgIHwKCui1hOaWmeadpea6kO+8mklRVklB77yM5Lit5rOw6K+B5Yi456CU56m25omA
AK104治疗一线宫颈癌对比联合疗法适用患者增加PD-L1CPS<1部分,III期研究已达PFS终点_第3页
AK104治疗一线宫颈癌对比联合疗法适用患者增加PD-L1CPS<1部分,III期研究已达PFS终点_第4页
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
AK104治疗一线宫颈癌对比联合疗法适用患者增加PD-L1CPS<1部分,III期研究已达PFS终点_第5页
所属报告: 康方生物-港股公司研究报告-双特异抗体龙头国际化之路现胜利曙光-240621(37页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠